Liquidia Co. (NASDAQ:LQDA - Get Free Report) insider Jason Adair sold 1,856 shares of Liquidia stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $25,185.92. Following the completion of the transaction, the insider now owns 184,304 shares in the company, valued at approximately $2,501,005.28. This represents a 1.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Jason Adair also recently made the following trade(s):
- On Monday, January 27th, Jason Adair sold 445 shares of Liquidia stock. The stock was sold at an average price of $14.20, for a total transaction of $6,319.00.
Liquidia Price Performance
Shares of LQDA stock opened at $13.60 on Wednesday. The stock has a market capitalization of $1.16 billion, a PE ratio of -8.34 and a beta of 0.23. The business's 50 day simple moving average is $14.79 and its 200 day simple moving average is $12.72. Liquidia Co. has a one year low of $8.26 and a one year high of $16.81.
Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The firm had revenue of $2.92 million during the quarter, compared to the consensus estimate of $4.60 million. As a group, research analysts expect that Liquidia Co. will post -1.51 earnings per share for the current year.
Institutional Trading of Liquidia
A number of institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Liquidia in the 1st quarter valued at about $911,000. GAMMA Investing LLC lifted its stake in Liquidia by 65.6% in the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock valued at $44,000 after buying an additional 1,173 shares during the period. Rhumbline Advisers boosted its holdings in shares of Liquidia by 6.0% during the 1st quarter. Rhumbline Advisers now owns 85,463 shares of the company's stock worth $1,261,000 after buying an additional 4,811 shares in the last quarter. Whitcomb & Hess Inc. grew its position in shares of Liquidia by 85.3% during the 1st quarter. Whitcomb & Hess Inc. now owns 21,300 shares of the company's stock worth $314,000 after buying an additional 9,805 shares during the period. Finally, California State Teachers Retirement System increased its stake in shares of Liquidia by 17.5% in the 4th quarter. California State Teachers Retirement System now owns 51,928 shares of the company's stock valued at $611,000 after acquiring an additional 7,725 shares in the last quarter. Institutional investors own 64.54% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on LQDA. Scotiabank restated an "outperform" rating on shares of Liquidia in a research report on Thursday, March 20th. Needham & Company LLC reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Liquidia in a research note on Thursday, April 10th. HC Wainwright reiterated a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a report on Thursday, March 20th. Finally, Wells Fargo & Company started coverage on shares of Liquidia in a report on Friday, December 20th. They set an "overweight" rating and a $20.00 target price on the stock. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $26.63.
Read Our Latest Stock Report on Liquidia
About Liquidia
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
